) The Human Tissue and Pathology Core has been an essential facility of the Comprehensive Cancer Center (CCC) for more than a decade. The Core provides investigators in the CCC with thousands of human tissue samples necessary for research purposes. The Core facility is charged with harvest, storage, and transfer of fresh and frozen human tissue samples for investigative purposes, within the established rules of the Human Investigation Committee. In addition, a complete and accurate pathological diagnosis including staging and grading parameters is available for subsets of the collection; ancillary studies are performed and are accessible. The recent acquisition of a laser microdissection system and the expansion of the tissue acquisition function to incorporate histologic processing and immunohistochemical staining broaden the scope of the Core's services and collaborations. A variety of funded investigators in the Prostate Cancer, Breast Cancer, Developmental Therapeutics, Population Studies and Prevention, Proteases and Molecular Biology and Genetics Programs utilize the services of the Core and have scientific collaborations with Core investigators. A common theme is translational research to predict the behavior and aggressiveness of different tumors, their tendency to develop, progress and/or recur and their response to treatment. A major emphasis is the molecular basis and profiles for the outcome trends in the diverse populations served by the CCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-22S1
Application #
6503905
Study Section
Project Start
2001-09-27
Project End
2001-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications